Pacing for Pressure: The Clinical Efficacy of AVIM Therapy in Hypertension Management

Resistant hypertension affects approximately 10–15% of hypertensive patients despite optimized pharmacologic therapy, necessitating novel interventions. Atrioventricular Interval Modulation (AVIM) therapy is an emerging device-based approach that utilizes dual-chamber pacemakers to simultaneously address standard pacing indications and uncontrolled blood pressure. Unlike conventional pacing, AVIM leverages continuous cycles of short atrioventricular delays to effectively reduce ventricular preload and arterial afterload. These short delays are strategically interspersed with native-like, longer atrioventricular intervals that generate intermittent, higher-pressure pulses. This cyclical asymmetry tricks the body’s baroreflex, successfully suppressing compensatory sympathetic vasoconstriction and lowering total peripheral resistance. Pilot trials (MODERATO I and II) demonstrate significant, durable reductions in ambulatory systolic blood pressure while maintaining cardiac contractility and energy efficiency. Furthermore, integrating AVIM with modern conduction system pacing, specifically left bundle branch area pacing, has refined the therapy. Left bundle branch area pacing-AVIM preserves native-like electrical synchrony and substantially outperforms traditional right ventricular pacing, achieving systolic blood pressure reductions of up to 24.1 mm Hg. The therapy also demonstrates rapid, restorative benefits for patients with concurrent diastolic dysfunction, promoting favorable reverse left ventricular remodeling. Ultimately, AVIM presents a continuous, nonpharmacological alternative for managing hypertension, circumventing the pervasive challenges of polypharmacy and medication nonadherence.